Deals and Financings
• MGI Tech a Shenzhen maker of gene sequencing machines and a subsidiary of genomics company BGI, completed an A funding of more than $200 million;
• Xynomic Pharma closed its business combination with Bison Capital Acquisition, becoming a wholly-owned subsidiary of BCAC in a $191.6 million deal;
• HanX Biopharma, a China oncology company, in-licensed China rights to a Phase III candidate for myelodysplastic syndromes from Onconova in a $51.5 million agreement;
• AnHeart Therapeutics of Hangzhou raised $14.6 million to develop in-licensed oncology drugs in a Series A round from Decheng Capital;
• US-based Leads Biolabs, a fully-owned subsidiary of Nanjing Leads Biolabs, granted Pneuma a license to develop inhaled versions of Leads' immuno-oncology candidates;
• China's Winhealth Pharma in-licensed greater China rights for two FDA approved pain management drugs from Cumberland Pharma;
• Shenzhen Mindray signed an agreement allowing it to use Masimo's technology for noninvasive, continuous measurement of pulse oximetry;
• Shanghai ChemPartner, a China CRO, installed Berkeley Lights' Beacon® Optofluidic platform to offer B Cell antibody discovery services;
Company News
• WuXi Biologics, a China biologics CRO/CMO, began building a large manufacturing center for innovative biologics in Chengdu;
Trials and Approvals
• Suzhou's Innovent and its partner Lilly announced their anti-CD20 biosimilar to Rituxan met its primary endpoints in two China clinical trials.
Stock Symbols: (NSDQ: BCAC) (NSDQ: CPIX) (NSDQ: MASI) (SHZ: 300760) (NSDQ: ONTX) (HK: 2269) (HK: 01801) (NYSE: LLY)
Share this with colleagues: